Here's Why Biogen's Big Gain Won't Last Long
Millions of Alzheimer's disease patients, their families, and their friends felt their hearts sink when Biogen (NASDAQ: BIIB) broke the bad news that an experimental Alzheimer's therapy, aducanumab, had failed a pivotal study. Overnight, the biotech giant's market value was cut in half, but a recent announcement has helped the stock recover most of those losses.
Biogen told us that aducanumab failed an interim futility analysis seven months ago, but now the company's arguing that it was wrong and the Alzheimer's candidate actually succeeded. According to the company, another look at a larger set of data actually proves there was a significant benefit.
Image source: Getty Images.
Source Fool.com
